Dynamic Technology Lab Private Ltd Acquires 1,957 Shares of Johnson & Johnson (NYSE:JNJ)

Dynamic Technology Lab Private Ltd increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 114.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,660 shares of the company's stock after buying an additional 1,957 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Johnson & Johnson were worth $529,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC boosted its position in Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after buying an additional 1,561,036 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $4,390,037,000. Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Johnson & Johnson by 3.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company's stock valued at $2,630,216,000 after purchasing an additional 547,714 shares during the period. Institutional investors own 69.55% of the company's stock.

Remove Ads

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research report on Tuesday, January 28th. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $163.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Finally, Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $171.67.

Johnson & Johnson Stock Up 1.4 %

Shares of Johnson & Johnson stock traded up $2.10 during trading hours on Friday, reaching $150.79. The company's stock had a trading volume of 2,934,409 shares, compared to its average volume of 9,834,769. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock's fifty day simple moving average is $159.43 and its two-hundred day simple moving average is $155.27. The company has a market capitalization of $363.39 billion, a P/E ratio of 22.66, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.